DDInter471 DDInter899
Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans. The active constituents are heparan, dermatan and, and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa). It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients. Danaproid is used in the treatment of heparin-induced thrombocytopenia (HIT) as an off-label indication and prevention of post-operative deep venous thrombosis (DVT). While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Danaparoid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Danaparoid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amiloride
Danaparoid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Protein C
Danaparoid {u} may lead to a major life threatening interaction when taken with {v} Desirudin
Danaparoid {u} may lead to a major life threatening interaction when taken with {v} Ibritumomab tiuxetan
Danaparoid may cause a minor interaction that can limit clinical effects when taken with Chamomile
Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Protein C
Danaparoid may lead to a major life threatening interaction when taken with Desirudin
Danaparoid may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan